Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis
Nicolò Moschetta(Vita-Salute San Raffaele University), Davide Mileto, Angelo Roberto Raccagni(Vita-Salute San Raffaele University), Antonella Castagna(Vita-Salute San Raffaele University), Riccardo Lolatto(Vita-Salute San Raffaele University), Caterina Candela(Vita-Salute San Raffaele University), Silvia Nozza(IRCCS Ospedale San Raffaele), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Sara Diotallevi(Vita-Salute San Raffaele University), Micol Bianchi, Maria Rita Gismondo(Luigi Sacco Hospital)
Cited by 37
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
|New England Journal of Medicine|2022|312
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
|Critical Care and Resuscitation|2020|229